Thymus May Hold Clue To Rebuilding Immune System After HIV
May 1st 1999Discovery of a marker that allows tracking of thymus function also shows how the adult immune system might repair itself after being damaged by the human immunodeficiency virus (HIV), UT Southwestern Medical Center at Dallas scientists report
Task Force to Evaluate Vitamins, Pharmacologics as Cancer Prophylaxis
May 1st 1999ROCKVILLE, Md-Two cancer-related topics are among four new evaluations the Agency for Health Care Policy and Research (AHCPR) has asked the U.S. Preventive Services Task Force to make. The task force is an independent panel of preventive health experts that evaluates the effectiveness of a wide range of clinical preventive services.
NCI Program Aims at Reducing Cancer Burden Among Minorities, the Poor
May 1st 1999BETHESDA, Md-The National Cancer Institute (NCI) has earmarked $30 million for use over the next 5 years to support a group of projects that will unite research scientists and community leaders in efforts to address disparities in national cancer rates among minorities and other underserved groups.
Legislation Would Carve Out Cancer From HCFA-Proposed APCs
May 1st 1999ALEXANDRIA, Va-“The Health Care Finance Agency’s plan to reimburse for outpatient Medicare cancer treatment according to ambulatory payment classifications (APCs) would have a crippling effect on research and development of new drug therapies and lower the quality of care for present and future cancer patients,” Congressman Gene Green, Representative of the 29th District of Texas in the US House of Representatives, said at the Annual Meeting of the Association of Community Cancer Centers (ACCC).
NCI Announces Sites of First Endostatin Phase I Studies
May 1st 1999BETHESDA, Md-The first human trials of the antiangiogenesis drug endostatin will take place at the University of Wisconsin-Madison and the University of Texas M.D. Anderson Cancer Center. The National Cancer Institute (NCI), which will sponsor the phase I trials, said that the studies will begin in late summer or early fall. Protocols for the two studies had not been worked out at the time of the NCI’s announcement.
New Agents Have Altered ‘Therapeutic Paradigm’ of NHL
May 1st 1999We are entering an extraordinary era in the treatment of patients with indolent non-Hodgkin’s lymphomas (NHL). Several decades were devoted to expending resources on comparing combinations and permutations of conventional agents, but with no beneficial impact on survival.
Danish Perspectives in Oncology: Profiles From Aarhus
May 1st 1999While in Denmark under an ASTRO/ESTRO fellowship travel grant, Dr. Brian Kavanagh spoke with a number of oncologists at the University of Aarhus about their research and the practice of oncology in Denmark. In this essay, he skillfully weaves Danish history, philosophy, customs, and landscape into his interviews with four eminent Danish physicians.
Cost Modeling for Alternate Routes of Administration of Opioids for Cancer Pain
May 1st 1999The economic considerations relative to neuraxial infusion can be looked at with different types of economic models, including cost-minimization, cost-effectiveness, and cost-benefit analyses. A theoretical predictive model
A 15-Year-Old Boy With Primitive Neurectodermal Tumor
Dr. Peter Staats presented the case of a 15-year-old, 40-kg boy with a primitive neurectodermal tumor located in
Neuraxial Infusion for Pain Control: When, Why, and What to Do After the Implant
May 1st 1999Neuraxial infusion therapy is an excellent option for selected patients with severe pain. Both epidural and intrathecal systems can be effective for multiple pains and are titratable, nondestructive, and very safe.
Who Smokes? A Profile of Smokers in the US
April 1st 1999ATLANTA-In 1995, an estimated 47 million adults in the United States were current smokers. A “Profile of Smokers” from the American Cancer Society’s Cancer Facts & Figures-1999 shows that, in that year, smoking prevalence was higher for men (27%) than women (22.6%) and highest among American Indians/Alaskan natives (36.2%), compared with other racial and ethnic groups.
What We’re Learning About the Analgesic Effects of Cannabinoids
April 1st 1999NEW YORK-“Up until about 10 years ago, we had no clear vision about what marijuana does in the brain,” Billy R. Martin, PhD, professor of pharmacology, Medical College of Virginia, said at the Third Conference on Pain Management and Chemical Dependency.
Modeling Cancer Risks ‘Problematic But Still Useful’
April 1st 1999ANAHEIM, Calif-“Mathematical modeling of cancer risk involves a number of unknown or inadequately understood relationships and factors, but still can provide worthwhile hypotheses for further testing,” Troyce Jones, MS, senior research scientist, Oak Ridge National Laboratory, said at a symposium on environmental hazards and cancer at the annual meeting of the American Association for the Advancement of Science (AAAS).